Combined antihypertensive and lipid-lowering treatment (original) (raw)

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497. This report constitutes the US updated guidelines for cholesterol testing and management in primary and secondary prevention.
  Article Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601–1610. The current European guidelines on CVD prevention define the risk in terms of the absolute 10-year probability of fatal CVD according to the SCORE chart.
  Article PubMed Google Scholar
• Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13:3S-10S.
  Article PubMed CAS Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011–1053. The current European guidelines for the management of arterial hypertension are prepared by a combined Committee from the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC), and stress the importance of evaluating all major CV risk factors to define the individual risk profile.
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999, 17:151–183.
• Conroy RM, Pyorala K, Fitzgerald AP, et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987–1003. The SCORE project has provided tables that predict 10-year risk of fatal CVD separately for higher- and lower-risk countries in Europe.
  Article PubMed CAS Google Scholar
• Kannel WB: Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988, 62:1109–1112.
  Article PubMed CAS Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.
  Article PubMed CAS Google Scholar
• Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.
  Article PubMed CAS Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.
• Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335:1001–1009.
  Article PubMed CAS Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349–1357.
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22. This is the largest statin trial, including more than 20,000 patients, most of whom have established vascular disease.
• U.S. Department of Health and Human Services (DHHS): National Centre for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994. NHANES III Examination Data File (CD ROM). Public Use Data File Documentation Number 76200. Hyattsville, MD: Centers for Disease Control and Prevention; 1996.
  Google Scholar
• Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303–1307.
  Article PubMed CAS Google Scholar
• Kristianson K, Fyhrquist F, Devereux RB, et al.: An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension LIFE Study. Clin Ther 2003, 25:1186–1199.
  Article PubMed CAS Google Scholar
• Cesari M, Maiolino G, Colonna S, et al.: Undertreatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol 2003, 42:484–490. This study comprised a large Italian population and confirmed the US findings of low implementation of guidelines in clinical practice.
  Article PubMed CAS Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158. This primary prevention trial showed a marked reduction of CV events in the group treated with atorvastatin, compared with placebo, and in hypertensive patients who were not conventionally deemed dyslipidemic.
  Article PubMed CAS Google Scholar
• Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997, 278:313–321.
  Article PubMed CAS Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10–17.
  Article PubMed CAS Google Scholar
• Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:56–64.
  Article PubMed CAS Google Scholar
• Thomas F, Bean K, Guize L, et al.: Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women. Eur Heart J 2002, 23:528–535.
  Article PubMed CAS Google Scholar
• Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303–1307.
  Article PubMed CAS Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipidlowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459–467.
  Article PubMed CAS Google Scholar
• Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605–613.
  Article PubMed CAS Google Scholar
• Byington RP, Davis BR, Plehn JF, et al.: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001, 103:387–392.
  PubMed CAS Google Scholar
• Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.
  PubMed CAS Google Scholar
• Waters D, Higginson L, Gladstone P, et al.: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959–968.
  PubMed CAS Google Scholar
• Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528–2540.
  PubMed CAS Google Scholar
• Mondillo S, Ballo P, Barbati R, et al.: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003, 114:359–364.
  Article PubMed CAS Google Scholar
• Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643–1650.
  Article PubMed CAS Google Scholar
• Yang Z, Kozai T, van der LB, et al.: HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000, 36:1691–1697.
  Article PubMed CAS Google Scholar
• Wassmann S, Laufs U, Muller K, et al.: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002, 22:300–305.
  Article PubMed CAS Google Scholar
• Kawashima S, Yamashita T, Miwa Y, et al.: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003, 34:157–163.
  Article PubMed CAS Google Scholar
• Yamashita T, Kawashima S, Miwa Y, et al.: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002, 20:2465–2473.
  Article PubMed CAS Google Scholar
• Hasegawa H, Yamamoto R, Takano H, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003, 35:953–960.
  Article PubMed CAS Google Scholar
• O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMGcoenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126–1131.
  PubMed CAS Google Scholar
• Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endotheliumdependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519–2524.
  PubMed CAS Google Scholar
• Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281–1286.
  PubMed CAS Google Scholar
• Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999, 83:1497–1499, A8.
  Article PubMed CAS Google Scholar
• Ferrier KE, Muhlmann MH, Baguet JP, et al.: Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002, 39:1020–1025.
  Article PubMed CAS Google Scholar
• Vasa M, Fichtlscherer S, Adler K, et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885–2890.
  PubMed CAS Google Scholar
• Orekhov AN, Tertov VV, Sobenin IA, et al.: Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int J Cardiol 1997, 62(Suppl 2):S67-S77.
  Article PubMed Google Scholar
• van de Poll SW, Delsing DJ, Jukema JW, et al.: Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 2003, 35:109–118.
  Article PubMed Google Scholar
• Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial Function). Circulation 2003, 107:422–428. This is the largest clinical trial investigating the effect of a statin-CCB combination on endothelial dysfunction in patients with stable CAD.
• Jukema JW, Zwinderman AH, van Boven AJ, et al.: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol 1996, 16:425–430.
  PubMed CAS Google Scholar
• Borghi C, Prandin MG, Costa FV, et al.: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000, 35:549–555.
  Article PubMed CAS Google Scholar
• Samuelsson O, Wilhelmsen L, Andersson OK, et al.: Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension: results from the primary prevention trial in Goteborg, Sweden. JAMA 1987, 258:1768–1776.
  Article PubMed CAS Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623–1630.
  Article PubMed CAS Google Scholar
• Sacks FM, Tonkin AM, Shepherd J, et al.: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893–1900. In the PPP project, the data from three large, randomized trials with pravastatin (WOSCOPS, CARE, and LIPID) were pooled and analyzed.
  PubMed CAS Google Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998–3007. In this trial, the benefits of the statin plus antihypertensive treatment in high-risk hypertensive patients with moderately elevated cholesterol levels were investigated; 10,355 patients were randomized, in an open-label design, to pravastatin or usual care.
• Gotto AM: Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002, 112(Suppl8A):19S-26S.
  Article PubMed CAS Google Scholar
• Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.
  PubMed CAS Google Scholar
• Etingin OR, Hajjar DP: Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. Circ Res 1990, 66:185–190.
  PubMed CAS Google Scholar
• Taddei S, Virdis A, Ghiadoni L, et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001, 37:943–948.
  PubMed CAS Google Scholar
• Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al.: Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990, 335:1109–1113.
  Article PubMed CAS Google Scholar
• Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785–791.
  Article PubMed CAS Google Scholar
• Zanchetti A, Bond MG, Hennig M, et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, doubleblind, long-term trial. Circulation 2002, 106:2422–2427.
  Article PubMed CAS Google Scholar
• Zanchetti A, Rosei EA, Dal Palu C, et al.: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998, 16:1667–1676.
  Article PubMed CAS Google Scholar